Avenue Therapeutics (ATXI) Stock Forecast, Price Target & Predictions
ATXI Stock Forecast
Avenue Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 597.67% upside from ATXI’s last price of $1.72) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ATXI Price Target
The average price target for Avenue Therapeutics (ATXI) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 597.67% upside from ATXI's last price of $1.72.
ATXI Analyst Ratings
According to 1 Wall Street analysts, Avenue Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ATXI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avenue Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Jason McCarthy | Maxim Group | $12.00 | $3.39 | 253.98% | 597.67% |
The latest Avenue Therapeutics stock forecast, released on Jun 07, 2024 by Jason McCarthy from Maxim Group, set a price target of $12.00, which represents a 253.98% increase from the stock price at the time of the forecast ($3.39), and a 597.67% increase from ATXI last price ($1.72).
Avenue Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $1.72 | $1.72 | $1.72 |
| Upside/Downside | -100.00% | -100.00% | 597.67% |
In the current month, the average price target of Avenue Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avenue Therapeutics's last price of $1.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 07, 2024 | Maxim Group | Buy | Buy | Hold |
Avenue Therapeutics's last stock rating was published by Maxim Group on Jun 07, 2024. The company gave ATXI a "Buy" rating, the same as its previous rate.
Avenue Therapeutics Financial Forecast
Avenue Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ATXI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Avenue Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict ATXI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Avenue Therapeutics's previous annual EBITDA (undefined) of $NaN.
Avenue Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-912.11K | $-1.50M | $-1.17M |
| High Forecast | $-912.11K | $-1.50M | $-1.17M |
| Low Forecast | $-912.11K | $-1.50M | $-1.17M |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATXI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Avenue Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Avenue Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ATXI last annual SG&A of $NaN (undefined).
Avenue Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.57 | $-0.94 | $-1.05 |
| High Forecast | $-0.57 | $-0.94 | $-1.05 |
| Low Forecast | $-0.57 | $-0.94 | $-1.05 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Avenue Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATXI previous annual EPS of $NaN (undefined).